期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 16, 期 4, 页码 463-476出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2016.1133582
关键词
Stem cell; Leukemia; Hypoxia; HIFs
资金
- Francis Crick Institute
- Cancer Research UK [15692] Funding Source: researchfish
- The Francis Crick Institute [10045] Funding Source: researchfish
Introduction: Hypoxia inducible factors (HIF-1 alpha and HIF-2 alpha) are the main mediators of hypoxic responses that operate in both normal and pathological conditions. Recent evidence indicates that HIF-1 alpha and HIF-2 alpha could have overlapping, unique and even sometimes opposing activities in both normal physiology and disease. Despite an increase in our understanding of the different pathways regulated by HIF-1 alpha and HIF-2 alpha, the role played by each factor in HSC maintenance and leukemogenesis is still controversial. Areas covered: This review summarizes our current understanding of HIF-1 alpha and HIF-2 alpha activities and discusses the implications and challenges of using HIF inhibitors therapeutically in blood malignancies. Expert opinion: As HIF inhibitors are currently under clinical evaluation in different cancers, including hematological malignancies, a more thorough understanding of the unique roles performed by HIF-1 alpha and HIF-2 alpha in human neoplasia is warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据